Virbac SA
PAR:VIRP

Watchlist Manager
Virbac SA Logo
Virbac SA
PAR:VIRP
Watchlist
Price: 339 EUR -0.59%
Market Cap: 2.8B EUR

EV/EBIT
Enterprise Value to EBIT

5.3
Current
12.2
Median
16.6
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
5.3
=
Enterprise Value
2.9B EUR
/
EBIT
551.5m EUR
All Countries
Close
Market Cap EV/EBIT
FR
Virbac SA
PAR:VIRP
2.8B EUR 5.3
US
Eli Lilly and Co
NYSE:LLY
936.4B USD 36.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 17 702.3
US
Johnson & Johnson
NYSE:JNJ
503.8B USD 21.3
CH
Roche Holding AG
SIX:ROG
250.8B CHF 13.3
UK
AstraZeneca PLC
LSE:AZN
209.7B GBP 159.3
CH
Novartis AG
SIX:NOVN
201.9B CHF 14.4
US
Merck & Co Inc
NYSE:MRK
243.9B USD 10.9
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 11
IE
Endo International PLC
LSE:0Y5F
202.5B USD 805.4
US
Pfizer Inc
NYSE:PFE
146.7B USD 10.3
EBIT Growth EV/EBIT to Growth
FR
Virbac SA
PAR:VIRP
Average EV/EBIT: 1 708.2
5.3
8%
0.7
US
Eli Lilly and Co
NYSE:LLY
36.7
36%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.3
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.3
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
159.3
23%
6.9
CH
Novartis AG
SIX:NOVN
14.4
12%
1.2
US
Merck & Co Inc
NYSE:MRK
10.9
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
11
1%
11
IE
E
Endo International PLC
LSE:0Y5F
805.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
8%
1.3

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
12.5
2-Years Forward
EV/EBIT
11.4
3-Years Forward
EV/EBIT
10.3